Many of the previous profiling studies also report a significant difference in compound sensitivity for cell lines grown in suspension vs other cancer types. Are such trends observed here?

Indeed we observe that cell lines from hematological origins, which are all grown in suspension, are more sensitive to some cytotoxic therapies. Some of this is also discussed in our earlier work (Uitdehaag et al. (2014)). We do not know if this originates from the way of growing, from the hematological lineage, or from the historic focus on leukemias for drug development.